Navigation Links
Kylin Therapeutics Receives Notice of Allowance for Second U.S. Patent Covering Delivery of Therapeutic RNA and pRNAi Technology
Date:10/4/2011

WEST LAFAYETTE, Ind., Oct. 4, 2011 /PRNewswire/ -- Kylin Therapeutics, Inc., a leading second-generation RNAi company, announced today that it has received a notice of allowance from United States Patent and Trademark Office (USPTO) for its second U.S. patent application. This newly allowed patent broadly covers new therapeutic RNA technology, as well as expanded areas on Kylin's proprietary nanoparticle technology platform, "pRNA" ("packaging RNA"). This new intellectual property covers multi-valent RNA structures broadly encompassing: tissue targeting, aptamer binding, receptor-mediated endocytosis, and RNA interference. "We continue to be gratified that the USPTO recognizes pRNA as an entirely unique platform in the crowded RNAi intellectual property space," said J. Eric Davis, J.D., President and Chief Executive Officer of Kylin Therapeutics, Inc.

Upon issuance, this will be Kylin's second U.S. patent. Along with its other issued and granted pRNA patents in Europe, Australia, and the United States, Kylin believes that this seminal patent family represents rare "new ground" in the field of RNAi and the delivery of therapeutic RNA. Kylin has a total of five patent families, with several other applications in the pipeline. "The unexpected, pharmacologically robust nature of the pRNA platform continues to allow Kylin to claim more ground in areas such as RNAi and tissue-specific targeting," said Homer Pearce, Ph.D., Director and Chairman of Kylin's Scientific Advisory Board.

Kylin's pRNA intellectual property estate is based upon the innovative discoveries of Peixuan Guo, Ph.D., and others at Kylin, on the design and creation of novel, therapeutically relevant RNA molecules. These molecules can be engineered as RNA multiplexes that function as RNAi-inducing DICER substrates and tissue-targeting modalities, and they can be used systemically and discretely without additional delivery components. Kylin has continued and expanded upon the work of Dr. Guo, demonstrating the improved pharmacokinetics of pRNA molecules in several relevant in vivo model systems, primarily in cancer.

"The pRNA patents are a result of Kylin's and Dr. Guo's visionary efforts to borrow from nature and create novel, therapeutically superior RNA molecules," said Davis. "We continue to believe this is an entirely new intellectual property landscape in the field of RNA-based therapeutics, one that is distinct and protectable from other patents in the RNAi and antisense fields."

Following a Notice of Allowance, the process resulting in final issuance of a patent involves a number of administrative steps that are typically completed in a few months.

About Kylin Therapeutics

Kylin Therapeutics, Inc., a second-generation RNAi company, employs a revolutionary RNA nanoparticle technology platform called "pRNA" to exploit the enormous potential of RNA interference (RNAi) for treatment of many common diseases. This visionary platform has enormous potential to meet the huge market opportunity for treating cancer and other diseases with RNA-based therapeutics. The unique capabilities of the platform have enabled Kylin to overcome the most significant challenges in the development of RNA-based therapies.

Contact: Eric Davis, Kylin Therapeutics, 919-386-9694, edavis@kylintherapeutics.com, http://www.kylintherapeutics.com

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com.


'/>"/>
SOURCE Kylin Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Skyline Diagnostics Establishes Research Collaboration With Janssen
2. Orexigen® Therapeutics Announces Multiple Contrave® Data Presentations at the 29th Annual Scientific Meeting of The Obesity Society
3. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
4. ALS Therapy Development Institute and Aestus Therapeutics, Inc., Expand Collaboration on Development of Novel ALS Therapies
5. Healthpoint Biotherapeutics to Present at UBS Global Life Sciences Conference
6. PharmaVentures Engaged by Astex Therapeutics to Assist in the Divestment of US Facility
7. CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
8. Debiopharm and Ascenta Therapeutics, Inc. Announce An Exclusive License Agreement for the Development and Commercialization of the IAP (Inhibitor of Apoptosis Protein) Inhibitor AT-406 (Called Debio 1143 by Debiopharm) for the Treatment of Various T
9. FierceBiotech Names Pearl Therapeutics a 2011 Fierce 15 Biotech
10. Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
11. PTC Therapeutics and Genzyme Announce Restructuring of Collaboration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... , ... October 11, 2017 , ... Disappearing forests and ... lives of over 5.5 million people each year. Especially those living in larger cities ... Treepex - based in one of the most pollution-affected countries globally - decided to ...
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), ... End-Use (Transportation & Logistics, Government & Public Sector, Utilities ... Generation Facility, Nuclear Power), Industrial, Retail, Business Organisation (BFSI), ... you looking for a definitive report on the $27.9bn ... ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/28/2017)... PUNE, India , March 28, 2017 ... (Analog, IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), ... Maintenance), Vertical, and Region - Global Forecast to 2022", ... 30.37 Billion in 2016 and is projected to reach ... 15.4% between 2017 and 2022. The base year considered ...
Breaking Biology News(10 mins):